Ken Griffin Tempest Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$2.01 - $5.44 $5,024 - $13,600
2,500 Added 3.21%
80,500 $176,000
Q1 2024

May 15, 2024
BUY
$3.16 - $4.66 $67,308 - $99,258
21,300 Added 37.57%
78,000 $304,000
Q4 2023

Feb 14, 2024
BUY
$0.23 - $9.77 $13,041 - $553,959
56,700 New
56,700 $249,000

Others Institutions Holding TPST

# of Institutions
28
Shares Held
1.72M
Call Options Held
30K
Put Options Held
80.5K
View Full List

About Tempest Therapeutics, Inc.

TPST Quotes by TradingView
  • Ticker TPST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,418,900
  • Market Cap $14.2M
  • Description
  • Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...
More about TPST
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email